免疫检查点抑制剂治疗相关胸腔积液的研究进展

安天棋; 田建辉; 周奕阳; 罗斌; 阙祖俊; 刘瑶; 于盼; 赵瑞华; 杨蕴

doi:10.19401/j.cnki.1007-3639.2025.03.010

您当前的位置：

首页 >

文章列表页 >

免疫检查点抑制剂治疗相关胸腔积液的研究进展

综述 | 更新时间：2025-12-31

- 免疫检查点抑制剂治疗相关胸腔积液的研究进展
- Research progress on treatment of pleural effusion related to immune checkpoint inhibitors
- 中国癌症杂志 2025年35卷第3期页码：333-338
- 作者机构：
  
  1. 上海中医药大学附属市中医医院肿瘤临床医学中心，上海中医药大学附属市中医医院肿瘤研究所，上海 200040
  2. 郑州大学第一附属医院肿瘤内科，郑州 450000
- 作者简介：
  
  [ "安天棋（ORCID: 0000-0002-6795-1658），博士研究生在读，住院医师。" ]
  杨蕴（ORCID: 0009-0000-4098-8496），副主任医师、硕士研究生导师。
- 基金信息：
  
  上海市卫生健康领军人才(2022LJ014);上海市进一步加快中医药传承创新发展三年行动计划(ZY(2021-2023)-0211)
- DOI：10.19401/j.cnki.1007-3639.2025.03.010
  中图分类号： R730.51
- 收稿：2024-10-18，
  
  修回：2024-12-11，
  
  纸质出版：2025-03-30
- 稿件说明：
移动端阅览
安天棋, 田建辉, 周奕阳, 等. 免疫检查点抑制剂治疗相关胸腔积液的研究进展[J]. 中国癌症杂志, 2025,35(3):333-338.

Tianqi AN, Jianhui TIAN, Yiyang ZHOU, et al. Research progress on treatment of pleural effusion related to immune checkpoint inhibitors[J]. China Oncology, 2025, 35(3): 333-338.
安天棋, 田建辉, 周奕阳, 等. 免疫检查点抑制剂治疗相关胸腔积液的研究进展[J]. 中国癌症杂志, 2025,35(3):333-338. DOI： 10.19401/j.cnki.1007-3639.2025.03.010.

Tianqi AN, Jianhui TIAN, Yiyang ZHOU, et al. Research progress on treatment of pleural effusion related to immune checkpoint inhibitors[J]. China Oncology, 2025, 35(3): 333-338. DOI： 10.19401/j.cnki.1007-3639.2025.03.010.

摘要

肿瘤免疫治疗作为一种新兴的治疗手段，近年来取得了显著进展，已成为继手术、放疗、化疗和靶向治疗之后的重要肿瘤治疗措施。特别是免疫检查点抑制剂（immune checkpoint inhibitors，ICIs）的临床应用，不仅提高了难治性或复发性肿瘤患者的生存率，也极大地优化了肿瘤治疗的整体策略。然而，随着接受免疫治疗的肿瘤患者人群的逐渐扩大，免疫治疗在带来临床获益的同时，也引发了一系列特殊的不良反应，即免疫相关不良反应（immune-related adverse events，irAEs）。在肿瘤患者中，胸腔积液是一种常见且严重的并发症，它对患者的生活质量和治疗效果均有显著影响。通常，肿瘤相关胸腔积液多为胸膜转移，恶性胸腔积液（malignant pleural effusion，MPE）产生迅速、难以控制且易反复。但随着新药物的批准以及现有药物适应证的拓展，接受ICIs治疗的癌症患者数量越来越多，ICIs治疗相关胸腔积液也逐渐引起了重视。ICIs治疗相关胸腔积液在临床上较为罕见，但其与患者的治疗选择和生存预后紧密相关。与MPE不同，ICIs治疗相关胸腔积液的发病机制更为复杂，除了非特异性的免疫激活导致自身免疫性炎症反应的发生外，还可能与胸膜结节病样肉芽肿反应、嗜酸粒细胞性慢性胸膜炎及肿瘤浸润性淋巴细胞相关。在诊断方面，ICIs治疗相关胸腔积液通常采用排除性诊断的方法，诊断过程中需排除肿瘤进展、放疗及化疗等其他肿瘤相关治疗引起的胸腔积液，这无疑增加了诊断的复杂性和难度。ICIs治疗相关胸腔积液的治疗多采用糖皮质激素、他克莫司或英夫利西单抗等药物，通过抑制过强的免疫反应来减轻患者的症状和改善预后。预防ICIs治疗相关胸腔积液的发生同样重要，这要求医师在应用ICIs前对患者进行综合评估，并在治疗期间持续监测，以期在早期发现并处理潜在的不良反应。通过这种综合管理方法，来最大限度地减少ICIs治疗相关胸腔积液对患者生活质量和治疗效果的影响，同时优化患者的整体治疗结果。本综述旨在探讨ICIs治疗相关胸腔积液的发病机制、病理学特征、临床表现、诊断方法及治疗策略等，通过深入分析ICIs治疗相关胸腔积液的特点，以期更好地理解这一并发症，为临床实践提供参考。

Abstract

Immunotherapy for cancer

as an emerging treatment modality

has made significant strides in recent years and has become a crucial therapeutic approach following surgery

radiotherapy

chemotherapy

and targeted therapy. In particular

the clinical utilization of immune checkpoint inhibitors (ICIs) has not only enhanced the survival rates of patients with refractory or recurrent tumors but has also significantly optimized the overall strategy for cancer treatment. However

as the population undergoing cancer immunotherapy continues to grow

this expansion not only yields clinical benefits but also precipitates a range of specific adverse reactions known as immune-related adverse events (irAEs). Pleural effusion is a common and severe complication in cancer patients

significantly affecting both their quality of life and treatment outcomes. Typically

tumor-related pleural effusion is often due to pleural metastasis

with malignant pleural effusion (MPE) characterized by rapid growth

being difficult to control

and tendency for recurrence. With the approval of new drugs and the expansion of indications for existing medications

the number of cancer patients receiving ICIs treatment is increasing

bringing ICIs-related pleural effusion into focus. While ICIs treatment-related pleural effusion is relatively rare in clinical practice

it is closely linked to treatment choices of patients and prognosis. Unlike MPE

the pathogenesis of ICIs treatment-related pleural effusion is more complex

not only involving non-specific immune activation leading to autoimmune inflammatory reactions but also potentially related to nodular pleural granulomatous reactions

eosinophilic chronic pleurisy

and tumor-infiltrating lymphocytes. In terms of diagnosis

ICIs treatment-related pleural effusion is typically diagnosed through exclusion

requiring the exclusion of other causes such as tumor progression

radiotherapy

and chemotherapy-induced pleural effusion

adding complexity and difficulty to the diagnostic process. Treatment for ICIs treatment-related pleural effusion often involves glucocorticoids

tocilizumab

or infliximab

aiming to alleviate symptoms and improve prognosis by suppressing excessive immune reactions. Preventing the occurrence of ICIs treatment-related pleural effusion is equally crucial

necessitating comprehensive patient assessment before ICIs administration and continuous monitoring during treatment to promptly detect and manage potential adverse reactions. Through this comprehensive management approach

the impact of ICIs treatment-related pleural effusion on patient quality of life and treatment outcomes can be minimized

optimizing overall treatment results. This review aimed to explore the pathogenesis

histological features

clinical manifestations

diagnostic methods and treatment strategies of ICIs treatment-related pleural effusion

and delve into the characteristics of ICIs treatment-related pleural effusion

in order to enhance understanding of this complication and provide a reference for clinical practice.

关键词

Keywords

references

GONNELLI F , HASSAN W , BONIFAZI M , et al . Malignant pleural effusion: current understanding and therapeutic approach [J ] . Respir Res , 2024 , 25 ( 1 ): 47 .

徐逸冰 , 张沂平 , 王文娴 . 恶性胸腔积液在肺癌中的研究进展 [J ] . 实用肿瘤杂志 , 2021 , 36 ( 1 ): 89 - 94 .

XU Y B , ZHANG Y P , WANG W X . Research progress of malignant pleural effusion in lung cancer [J ] . J Pract Oncol , 2021 , 36 ( 1 ): 89 - 94 .

周书含 , 于雁 , 张梦珂 . 肺癌相关恶性胸腔积液预测模型的研究进展 [J ] . 肿瘤 , 2023 , 43 ( 8 ): 684 - 691 .

ZHOU S H , YU Y , ZHANG M K . Research progress on prediction model of malignant pleural effusion associated with lung cancer [J ] . Tumor , 2023 , 43 ( 8 ): 684 - 691 .

PENZ E , WATT K N , HERGOTT C A , et al . Management of malignant pleural effusion: challenges and solutions [J ] . Cancer Manag Res , 2017 , 9 : 229 - 241 . DOI: 10.2147/CMAR.S95663 http://doi.org/10.2147/CMAR.S95663

KARAMPINIS I , DIONYSOPOULOU A , GALATA C , et al . Hyperthermic intrathoracic chemotherapy for the treatment of malignant pleural effusion caused by breast and ovarian cancer: a systematic literature review and pooled analysis [J ] . Thorac Cancer , 2022 , 13 ( 7 ): 883 - 888 . DOI: 10.1111/1759-7714.14361 http://doi.org/10.1111/1759-7714.14361

QURESHI M , THAPA B , MURUGANANDAN S . A narrative review-management of malignant pleural effusion related to malignant pleural mesothelioma [J ] . Heart Lung Circ , 2023 , 32 ( 5 ): 587 - 595 .

KONG X Q , ZHANG J Y , CHEN S W , et al . Immune checkpoint inhibitors: breakthroughs in cancer treatment [J ] . Cancer Biol Med , 2024 , 21 ( 6 ): 451 - 472 .

RUI R , ZHOU L Q , HE S M . Cancer immunotherapies: advances and bottlenecks [J ] . Front Immunol , 2023 , 14 : 1212476 .

MARTIN-LIBERAL J , KORDBACHEH T , LARKIN J . Safety of pembrolizumab for the treatment of melanoma [J ] . Expert Opin Drug Saf , 2015 , 14 ( 6 ): 957 - 964 .

TOPALIAN S L , SZNOL M , MCDERMOTT D F , et al . Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab [J ] . J Clin Oncol , 2014 , 32 ( 10 ): 1020 - 1030 . DOI: 10.1200/JCO.2013.53.0105 http://doi.org/10.1200/JCO.2013.53.0105

MOUNTZIOS G , REMON J , HENDRIKS L E L , et al . Immune-checkpoint inhibition for resectable non-small-cell lung cancer-opportunities and challenges [J ] . Nat Rev Clin Oncol , 2023 , 20 ( 10 ): 664 - 677 .

CHONG X , MADETI Y , CAI J , et al . Recent developments in immunotherapy for gastrointestinal tract cancers [J ] . J Hematol Oncol , 2024 , 17 ( 1 ): 65 .

DONNE R , LUJAMBIO A . The liver cancer immune microenvironment: therapeutic implications for hepatocellular carcinoma [J ] . Hepatology , 2023 , 77 ( 5 ): 1773 - 1796 .

BLUM S M , ROUHANI S J , SULLIVAN R J . Effects of immune-related adverse events (irAEs) and their treatment on antitumor immune responses [J ] . Immunol Rev , 2023 , 318 ( 1 ): 167 - 178 . DOI: 10.1111/imr.13262 http://doi.org/10.1111/imr.13262

RAMOS-CASALS M , SISÓ-ALMIRALL A . Immune-related adverse events of immune checkpoint inhibitors [J ] . Ann Intern Med , 2024 , 177 ( 2 ): ITC17-ITC32.

RAMOS-CASALS M , BRAHMER J R , CALLAHAN M K , et al . Immune-related adverse events of checkpoint inhibitors [J ] . Nat Rev Dis Primers , 2020 , 6 ( 1 ): 38 .

张旭 , 梁静 , 哈福双 , 等 . 肿瘤免疫治疗相关不良反应的预测因素 [J ] . 癌症进展 , 2023 , 21 ( 1 ): 10 - 14 .

ZHANG X , LIANG J , HA F S , et al . Predictors of adverse reactions related to tumor immunotherapy [J ] . Oncol Prog , 2023 , 21 ( 1 ): 10 - 14 .

SAWADA R , MATSUI Y , UCHINO J , et al . Late-onset pleural and pericardial effusion as immune-related adverse events after 94 cycles of nivolumab [J ] . Intern Med , 2021 , 60 ( 22 ): 3585 - 3588 .

OKIYAMA N , TANAKA R . Immune-related adverse events in various organs caused by immune checkpoint inhibitors [J ] . Allergol Int , 2022 , 71 ( 2 ): 169 - 178 . DOI: 10.1016/j.alit.2022.01.001 http://doi.org/10.1016/j.alit.2022.01.001

POTO R , TROIANI T , CRISCUOLO G , et al . Holistic approach to immune checkpoint inhibitor-related adverse events [J ] . Front Immunol , 2022 , 13 : 804597 .

SUIJKERBUIJK K P M , VAN EIJS M J M , VAN WIJK F , et al . Clinical and translational attributes of immune-related adverse events [J ] . Nat Cancer , 2024 , 5 ( 4 ): 557 - 571 .

NEGRINI D , MORIONDO A . Pleural function and lymphatics [J ] . Acta Physiol (Oxf) , 2013 , 207 ( 2 ): 244 - 259 . DOI: 10.1111/apha.12016 http://doi.org/10.1111/apha.12016

SHEN-WAGNER J , GAMBLE C , MACGILVRAY P . Pleural effusion: diagnostic approach in adults [J ] . Am Fam Physician , 2023 , 108 ( 5 ): 464 - 475 .

GAYEN S . Malignant pleural effusion: presentation, diagnosis, and management [J ] . Am J Med , 2022 , 135 ( 10 ): 1188 - 1192 . DOI: 10.1016/j.amjmed.2022.04.017 http://doi.org/10.1016/j.amjmed.2022.04.017

SMITH D A , RADZINSKY E , TIRUMANI S H , et al . Findings on chest CT performed in the emergency department in patients receiving immune checkpoint inhibitor therapy: single-institution 8-year experience in 136 patients [J ] . AJR Am J Roentgenol , 2021 , 217 ( 3 ): 613 - 622 .

MOK T S K , WU Y L , KUDABA I , et al . Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial [J ] . Lancet , 2019 , 393 ( 10183 ): 1819 - 1830 . DOI: S0140-6736(18)32409-7 http://doi.org/S0140-6736(18)32409-7

KORNEPATI A V R , VADLAMUDI R K , CURIEL T J . Programmed death ligand 1 signals in cancer cells [J ] . Nat Rev Cancer , 2022 , 22 ( 3 ): 174 - 189 . DOI: 10.1038/s41568-021-00431-4 http://doi.org/10.1038/s41568-021-00431-4

SHIRAVAND Y , KHODADADI F , KASHANI S M A , et al . Immune checkpoint inhibitors in cancer therapy [J ] . Curr Oncol , 2022 , 29 ( 5 ): 3044 - 3060 . DOI: 10.3390/curroncol29050247 http://doi.org/10.3390/curroncol29050247

POSTOW M A , SIDLOW R , HELLMANN M D . Immune-related adverse events associated with immune checkpoint blockade [J ] . N Engl J Med , 2018 , 378 ( 2 ): 158 - 168 .

BENN B S , LOMBARD C M , KRISHNA G . Nivolumab-induced granulomatous inflammation of the pleura [J ] . J Thorac Oncol , 2017 , 12 ( 7 ): e100-e101.

LIN J L , SABATH B F . Chronic pleuritis and recurrent pleural effusion after atezolizumab for small cell lung cancer [J ] . Am J Case Rep , 2021 , 22: e933396.

YANAGIHARA T , TANAKA K , OTA K , et al . Tumor-infiltrating lymphocyte-mediated pleuritis followed by marked shrinkage of metastatic kidney cancer of the chest wall during nivolumab treatment [J ] . Ann Oncol , 2017 , 28 ( 8 ): 2038 - 2039 . DOI: 10.1093/annonc/mdx214 http://doi.org/10.1093/annonc/mdx214

刘晔 , 王立峰 . 恶性胸腔积液诊治的研究进展 [J ] . 肿瘤防治研究 , 2024 , 51 ( 10 ): 877 - 882 .

LIU Y , WANG L F . Progress of research on diganosis and treatment of malignant pleural effusion [J ] . Cancer Res Prev Treat , 2024 , 51 ( 10 ): 877 - 882 .

曾灏 , 田攀文 . 恶性胸腔积液的诊断研究进展 [J ] . 中华肺部疾病杂志(电子版) , 2021 , 14 ( 2 ): 247 - 249 .

ZENG H , TIAN P W . Advances in diagnosis of malignant pleural effusion [J ] . Chin J Lung Dis Electron Ed , 2021 , 14 ( 2 ): 247 - 249 .

JANY B , WELTE T . Pleural effusion in adults-etiology, diagnosis, and treatment [J ] . Dtsch Arztebl Int , 2019 , 116 ( 21 ): 377 - 386 . DOI: 10.3238/arztebl.2019.0377 http://doi.org/10.3238/arztebl.2019.0377

BIBBY A C , DORN P , PSALLIDAS I , et al . ERS/EACTS statement on the management of malignant pleural effusions [J ] . Eur J Cardiothorac Surg , 2019 , 55 ( 1 ): 116 - 132 . DOI: 10.1093/ejcts/ezy258 http://doi.org/10.1093/ejcts/ezy258

SHEN C A , YEH Y C , CHIU C H . Progressive pleural effusion as an immune-related adverse event in NSCLC: a case report [J ] . JTO Clin Res Rep , 2021 , 2 ( 5 ): 100156 .

XIE X H , SHEN P X , WU J H , et al . Recurrent pleural effusion as a rare manifestation after prolonged PD1 inhibitor (camrelizumab)-based immunotherapy: a case report [J ] . Hum Vaccin Immunother , 2023 , 19 ( 2 ): 2240689 .

CHEN M Y , ZENG Y C . Pseudoprogression in lung cancer patients treated with immunotherapy [J ] . Crit Rev Oncol Hematol , 2022 , 169 : 103531 .

LIGHT R W , MACGREGOR M I , LUCHSINGER P C , et al . Pleural effusions: the diagnostic separation of transudates and exudates [J ] . Ann Intern Med , 1972 , 77 ( 4 ): 507 - 513 . DOI: 10.7326/0003-4819-77-4-507 http://doi.org/10.7326/0003-4819-77-4-507

孙美琪 , 张薇 , 郝倩文 , 等 . 肿瘤标志物对良恶性胸腔积液鉴别的研究进展 [J ] . 实用肿瘤杂志 , 2020 , 35 ( 3 ): 278 - 283 .

SUN M Q , ZHANG W , HAO Q W , et al . Research progress of tumor markers in differentiating benign from malignant pleural effusion [J ] . J Pract Oncol , 2020 , 35 ( 3 ): 278 - 283 .

BOTANA RIAL M , PÉREZ PALLARÉS J , CASES VIEDMA E , et al . Diagnosis and treatment of pleural effusion. Recommendations of the Spanish society of pulmonology and thoracic surgery. update 2022 [J ] . Arch Bronconeumol , 2023 , 59 ( 1 ): 27 - 35 .

SCHNEIDER B J , NAIDOO J , SANTOMASSO B D , et al . Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update [J ] . J Clin Oncol , 2021 , 39 ( 36 ): 4073 - 4126 .

HAANEN J , OBEID M , SPAIN L , et al . Management of toxicities from immunotherapy: ESMO clinical practice guideline for diagnosis, treatment and follow-up [J ] . Ann Oncol , 2022 , 33 ( 12 ): 1217 - 1238 . DOI: 10.1016/j.annonc.2022.10.001 http://doi.org/10.1016/j.annonc.2022.10.001

张诗民 , 陈元 , 褚倩 . 免疫检查点抑制剂治疗肿瘤的不良反应及管理策略 [J ] . 中国肿瘤临床 , 2018 , 45 ( 12 ): 609 - 613 .

ZHANG S M , CHEN Y , CHU Q . Management strategy for adverse events of immune checkpoint inhibitors [J ] . Chin J Clin Oncol , 2018 , 45 ( 12 ): 609 - 613 .

SKRIBEK M , ROUNIS K , AFSHAR S , et al . Effect of corticosteroids on the outcome of patients with advanced non-small cell lung cancer treated with immune-checkpoint inhibitors [J ] . Eur J Cancer , 2021 , 145 : 245 - 254 . DOI: 10.1016/j.ejca.2020.12.012 http://doi.org/10.1016/j.ejca.2020.12.012

HORVAT T Z , ADEL N G , DANG T O , et al . Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at memorial Sloan Kettering cancer center [J ] . J Clin Oncol , 2015 , 33 ( 28 ): 3193 - 3198 . DOI: 10.1200/JCO.2015.60.8448 http://doi.org/10.1200/JCO.2015.60.8448

CHEN C D , WANG C L , YU C J , et al . Targeted proteomics pipeline reveals potential biomarkers for the diagnosis of metastatic lung cancer in pleural effusion [J ] . J Proteome Res , 2014 , 13 ( 6 ): 2818 - 2829 .

SORINO C , MONDONI M , LOCOCO F , et al . Optimizing the management of complicated pleural effusion: from intrapleural agents to surgery [J ] . Respir Med , 2022 , 191 : 106706 .

FELLER-KOPMAN D J , REDDY C B , DECAMP M M , et al . Management of malignant pleural effusions. an official ATS/STS/STR clinical practice guideline [J ] . Am J Respir Crit Care Med , 2018 , 198 ( 7 ): 839 - 849 .

浏览量

778

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

中国抗癌协会乳腺癌诊治指南与规范（2026年版）

血液肿瘤合并实体肿瘤诊疗专家共识（2025年版）

免疫相关不良事件中糖皮质激素及免疫抑制剂管理策略对患者生存结局的影响：系统评价与Meta分析

肢端型黑色素瘤组织中MITF的表达及其与临床、病理学特征及预后的相关性研究

抗EGFR单抗联合免疫检查点抑制剂治疗头颈部鳞状细胞癌专家共识（2025年版）